Bristol-Myers Squibb Co. announced long-term pooled efficacy and safety results from the phase III CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small cell lung cancer.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe